Getting your Trinity Audio player ready...

Lately, several enterprises have surfaced in the media spotlight for various reasons, potentially catching the eye of investors. This article offers an in-depth examination of five companies that could be worthwhile to monitor.

Regulus Therapeutics Inc. (NASDAQ: RGLS) made headlines on March 12, 2024, following its declaration of securing approximately $100 million via a private equity placement to a group comprising accredited and institutional investors. The funding round exceeded expectations, with participation from both fresh and established investors, with plans for completion by March 14, 2024.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) stands out as a prominent medical technology firm renowned for its development of rapid, intelligent, and non-invasive testing solutions. On March 12, 2024, it finalized several securities purchase agreements from March 8, 2024, successfully concluding an offering valued at $10.1 million. With its stock boasting a low reported float, Intelligent Bio Solutions emerges as a compelling entity worth monitoring closely.

Catheter Precision Inc. (NYSE American: VTAK), a U.S.-based medical technology firm, has recently disclosed the deployment of its LockeT product for the first time beyond U.S. borders. This milestone occurred at the Heart Hospital of Hamad Medical Corporation in Doha, Qatar. The company’s VIVO, a non-invasive 3D imaging system aiding physicians in pinpointing the source of arrhythmias, has been gaining significant traction worldwide within the medical communities globally. Consequently, the stock has experienced a noteworthy upward surge in recent times.

Dyadic International Inc. (NASDAQ: DYAI), the biotechnology firm, has recently concluded a private offering worth $6 million. Notably, investors in this offering comprise immediate family members and family trusts associated with Mark Emalfarm, the company’s President and CEO. Among the participants in this private placement is the Francisco Trust, which holds a 5% stake in Dyadic’s outstanding stock.

TC BioPharm Holdings PLC (NASDAQ: TCBP), a clinical-stage biotechnology company, is engaged in advancing platform allogeneic gamma-delta T cell therapies for cancer treatment and other ailments. On February 22, 2024, the company declared that its proposed clinical trial authorization (CTA) had been formally approved by the MHRA. This amendment allows the company to elevate the dosage of gamma delta T-cells.